PedAM
Pediatric Disease Annotations & Medicines
| Disease | hypercalcemia |
| Symptom | C0026764|multiple myeloma |
| Sentences | 7 |
| PubMedID- 22073517 | multiple myeloma with hypercalcemia and chloride resistant metabolic alkalosis. |
| PubMedID- 26500541 | hypercalcemia in multiple myeloma may be the result of bone marrow infiltration and release of osteoclast-activating factors by the plasma cells 3. |
| PubMedID- 24334568 | It is the most common primary bone malignancy, and the extensive osteoclastic bone resorption common in multiple myeloma is associated with hypercalcemia in as many as one-third of patients. |
| PubMedID- 24743202 | Bisphosphonates(bps)have been widely used for the treatment of hypercalcemia associated with cancer, multiple myeloma bone diseases, and bone metastasis of solid cancers. |
| PubMedID- 23700375 | After the diagnosis of multiple myeloma with hypercalcemia, specific treatment was instigated, according to the following protocol (figure 2): intravenous normal saline (na, 154 mmol/l; cl, 154 mmol/l; 500 ml × 2/day; daily), dexamethasone (8 mg per day × 2 consecutive days), nahco3 (80 mmol/l per day; daily), bortezomib (1.3 mg/m2 per dose, weekly), elcatonin (40 units per day for 5 consecutive days), and zoledronic acid hydrate (4 mg per dose, monthly). |
| PubMedID- 25128013 | Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. |
| PubMedID- 21915243 | Interestingly, aminobisphosphonates (abs) which are synthetic compounds commonly used to treat bone disease and hypercalcemia in patients with multiple myeloma, breast or prostate cancer, have been identified also as antigens for γδ t cells, indicating these molecules as immunomodulating factors –. |
Page: 1